Suppressed DHA and arachidonic acid levels in brain tissue of PD patients (Fabelo et al., 2011); decreased plasmalogen levels in brain and blood of PD patients (Dragonas et al., 2009; Miville-Godbout et al., 2016).In mouse models of PD: plasmalogen-dependent decrease in striatal dopamine markers (Miville-Godbout et al., 2016); decreased catalase activity and suppressed Cat, Pex14 and Abcd3 mRNA levels in mice overexpressing-synuclein (Yakunin et al., 2014). The gene discussed is SNCA; the disease is Parkinson disease.